Figure 1
The clinical efficacy of osimertinib in advanced EGFR-mutant NSCLC patients. (A) The median progression-free survival. (B) The median overall survival. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer
Figure 1 | Scientific Reports
